CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Alzamend Neuro, Inc. - ALZN CFD

1.0091
4.72%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.0318
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026207 %
Charges from full value of position ($-1.05)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.026207%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003985 %
Charges from full value of position ($0.16)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
0.003985%
Overnight fee time 22:00 (UTC)
Min traded quantity 0.01
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 1.0591
Open* 1.0191
1-Year Change* -7.11%
Day's Range* 1.0091 - 1.0291
52 wk Range 1.06-19.20
Average Volume (10 days) 532.05K
Average Volume (3 months) 2.13M
Market Cap 7.05M
P/E Ratio -100.00K
Shares Outstanding 6.47M
Revenue N/A
EPS -2.36
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date Dec 12, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 8, 2023 1.0591 -0.0500 -4.51% 1.1091 1.1091 1.0291
Dec 7, 2023 1.0891 0.0300 2.83% 1.0591 1.1091 1.0391
Dec 6, 2023 1.0591 0.0500 4.95% 1.0091 1.0691 1.0091
Dec 5, 2023 1.0191 -0.0200 -1.92% 1.0391 1.0391 1.0091
Dec 4, 2023 1.0291 -0.0800 -7.21% 1.1091 1.1091 1.0091
Dec 1, 2023 1.1091 -0.0400 -3.48% 1.1491 1.1691 1.0991
Nov 30, 2023 1.1991 0.1000 9.10% 1.0991 1.1991 1.0891
Nov 29, 2023 1.1591 0.1600 16.01% 0.9991 1.1991 0.9991
Nov 28, 2023 1.0391 0.0700 7.22% 0.9691 1.0391 0.9691
Nov 27, 2023 0.9991 0.0100 1.01% 0.9891 1.0091 0.9591
Nov 24, 2023 1.0191 -0.0200 -1.92% 1.0391 1.0591 0.9991
Nov 22, 2023 1.0491 -0.0100 -0.94% 1.0591 1.0691 0.9764
Nov 21, 2023 1.0791 -0.1100 -9.25% 1.1891 1.1991 1.0491
Nov 20, 2023 1.3591 -0.3600 -20.94% 1.7191 1.8991 1.1291
Nov 17, 2023 1.6491 0.2300 16.21% 1.4191 1.6991 1.3991
Nov 16, 2023 1.4791 -0.0200 -1.33% 1.4991 1.4991 1.4091
Nov 15, 2023 1.4991 0.1300 9.50% 1.3691 1.5491 1.3691
Nov 14, 2023 1.3891 0.0800 6.11% 1.3091 1.4291 1.3091
Nov 13, 2023 1.3591 -0.0800 -5.56% 1.4391 1.4391 1.3191
Nov 10, 2023 1.4491 0.0500 3.57% 1.3991 1.4491 1.3991

Alzamend Neuro, Inc. Events

Time (UTC) Country Event
Tuesday, December 12, 2023

Time (UTC)

21:00

Country

US

Event

Q2 2024 Alzamend Neuro Inc Earnings Release
Q2 2024 Alzamend Neuro Inc Earnings Release

Forecast

-

Previous

-
Friday, March 15, 2024

Time (UTC)

20:00

Country

US

Event

Q3 2024 Alzamend Neuro Inc Earnings Release
Q3 2024 Alzamend Neuro Inc Earnings Release

Forecast

-

Previous

-
Thursday, April 25, 2024

Time (UTC)

16:00

Country

US

Event

Alzamend Neuro Inc Annual Shareholders Meeting
Alzamend Neuro Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2023 2022 2021 2020 2019
Total revenue 0 0 0 0 0
Total Operating Expense 14.8705 12.3155 4.88947 4.42416 5.00888
Selling/General/Admin. Expenses, Total 7.42461 7.11822 3.64117 3.35474 1.3088
Research & Development 7.44586 5.20131 1.31072 1.06942 3.70008
Operating Income -14.8705 -12.3155 -4.88947 -4.42416 -5.00888
Interest Income (Expense), Net Non-Operating -0.0077 -0.04652 -0.15709 0.01393 0.14639
Net Income Before Taxes -14.8782 -12.3621 -5.04657 -4.41024 -4.8625
Net Income After Taxes -14.8782 -12.3621 -5.04657 -4.41024 -4.8625
Net Income Before Extra. Items -14.8782 -12.3621 -5.04657 -4.41024 -4.8625
Net Income -14.8782 -12.3621 -5.04657 -4.41024 -4.8625
Income Available to Common Excl. Extra. Items -14.8782 -12.3621 -5.04657 -4.41024 -4.8625
Income Available to Common Incl. Extra. Items -14.8782 -12.3621 -5.04657 -4.41024 -4.8625
Diluted Net Income -14.8782 -12.3621 -5.04657 -4.41024 -4.8625
Diluted Weighted Average Shares 97.519 89.0953 84.9295 84.9295 84.9295
Diluted EPS Excluding Extraordinary Items -0.15257 -0.13875 -0.05942 -0.05193 -0.05725
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -0.15257 -0.1388 -0.06016 -0.05193 -0.05725
Unusual Expense (Income) 0 -0.004 -0.06242
Jul 2023 Apr 2023 Jan 2023 Oct 2022 Jul 2022
Total revenue 0 0 0 0 0
Total Operating Expense 3.52593 3.30501 5.42351 3.1064 3.03554
Selling/General/Admin. Expenses, Total 1.15979 1.65694 2.53467 1.57342 1.65959
Research & Development 2.36614 1.64807 2.88885 1.53299 1.37595
Unusual Expense (Income) 0
Operating Income -3.52593 -3.30501 -5.42351 -3.1064 -3.03554
Interest Income (Expense), Net Non-Operating -0.00184 -0.00052 -0.00206 -0.00359 -0.00153
Net Income Before Taxes -3.52777 -3.30553 -5.42557 -3.10999 -3.03707
Net Income After Taxes -3.52777 -3.30553 -5.42557 -3.10999 -3.03707
Net Income Before Extra. Items -3.52777 -3.30553 -5.42557 -3.10999 -3.03707
Net Income -3.52777 -3.30553 -5.42557 -3.10999 -3.03707
Income Available to Common Excl. Extra. Items -3.52777 -3.30553 -5.42557 -3.10999 -3.03707
Income Available to Common Incl. Extra. Items -3.52777 -3.30553 -5.42557 -3.10999 -3.03707
Diluted Net Income -3.52777 -3.30553 -5.42557 -3.10999 -3.03707
Diluted Weighted Average Shares 98.4401 96.7796 98.3262 97.4884 97.4818
Diluted EPS Excluding Extraordinary Items -0.03584 -0.03416 -0.05518 -0.0319 -0.03116
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.03584 -0.03416 -0.05518 -0.0319 -0.03116
  • Annual
  • Quarterly
2023 2022 2021 2020 2019
Total Current Assets 5.83578 14.4135 2.91259 1.81402 1.50092
Cash and Short Term Investments 5.14086 14.0638 1.92927 0.09029 0.04261
Cash 5.14086 14.0638 1.92927 0.09029 0.04261
Total Receivables, Net 0 0.01621 0.19428 0.28535
Accounts Receivable - Trade, Net 0 0.10092 0.20592
Prepaid Expenses 0.69492 0.34972 0.61461 1.52945 1.17296
Total Assets 5.91563 14.5164 2.91259 1.81402 1.50092
Total Current Liabilities 2.87012 1.16493 0.89964 0.99231 1.184
Payable/Accrued 2.87012 1.16285 0.50359 0.92964 1.10467
Notes Payable/Short Term Debt 0 0 0.3353 0 0
Other Current Liabilities, Total 0 0.00208 0.06075 0.06267 0.07933
Total Liabilities 2.87012 1.16493 0.89964 0.99231 1.184
Total Long Term Debt 0 0 0 0 0
Total Equity 3.0455 13.3515 2.01295 0.82171 0.31692
Redeemable Preferred Stock 0 0 0.00008 0.00008 0.00008
Common Stock 0.00969 0.00955 0.00674 0.00648 0.00619
Additional Paid-In Capital 61.9918 57.4198 33.7219 27.5842 22.6863
Retained Earnings (Accumulated Deficit) -44.0727 -29.1945 -16.8324 -11.7859 -7.37563
Other Equity, Total -14.8833 -14.8833 -14.8833 -14.9832 -15
Total Liabilities & Shareholders’ Equity 5.91563 14.5164 2.91259 1.81402 1.50092
Total Common Shares Outstanding 6.463 6.36577 5.66225 5.66225 5.66225
Other Current Assets, Total 0.3525
Property/Plant/Equipment, Total - Net 0.07984 0.10291
Jul 2023 Apr 2023 Jan 2023 Oct 2022 Jul 2022
Total Current Assets 2.4136 5.83578 8.41681 10.3344 12.1147
Cash and Short Term Investments 1.69542 5.14086 7.37584 9.18281 11.5271
Cash 1.69542 5.14086 7.37584 9.18281 11.5271
Total Receivables, Net 0.00941
Accounts Receivable - Trade, Net
Prepaid Expenses 0.71819 0.69492 1.04097 1.15158 0.57813
Total Assets 2.62801 5.91563 8.50198 10.4249 12.2105
Total Current Liabilities 2.74089 2.87012 2.64247 1.63745 1.0287
Payable/Accrued 2.74089 2.87012 2.64247 0.64812 1.0287
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0 0 0.98933 0
Total Liabilities 2.74089 2.87012 2.64247 1.63745 1.0287
Total Long Term Debt 0 0 0 0 0
Total Equity -0.11288 3.0455 5.85951 8.78742 11.1818
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.00969 0.00969 0.00964 0.00955 0.00955
Additional Paid-In Capital 62.3611 61.9918 61.5003 59.0027 58.2871
Retained Earnings (Accumulated Deficit) -47.6004 -44.0727 -40.7671 -35.3416 -32.2316
Other Equity, Total -14.8833 -14.8833 -14.8833 -14.8833 -14.8833
Total Liabilities & Shareholders’ Equity 2.62801 5.91563 8.50198 10.4249 12.2105
Total Common Shares Outstanding 6.463 6.463 6.42883 6.3666 6.36577
Other Current Assets, Total
Property/Plant/Equipment, Total - Net 0.2144 0.07984 0.08517 0.09049 0.09581
  • Annual
  • Quarterly
2022 2021 2020 2019
Net income/Starting Line -12.3621 -5.04657 -4.41024 -4.8625
Cash From Operating Activities -6.61399 -2.71203 -2.34579 -1.0452
Non-Cash Items 4.41734 2.48699 2.36379 2.58743
Changes in Working Capital 1.32718 -0.15245 -0.29935 1.22987
Cash From Investing Activities -0.10646 0.10092 0.105 0.23409
Other Investing Cash Flow Items, Total 0 0.10092 0.105 0.23409
Cash From Financing Activities 18.855 4.4501 2.28847 0.30872
Financing Cash Flow Items -0.05867 1.94799 0.00013 0.0727
Issuance (Retirement) of Stock, Net 18.9137 2.1 2.28834 0.23602
Net Change in Cash 12.1345 1.83899 0.04768 -0.5024
Issuance (Retirement) of Debt, Net 0 0.40211
Cash From Operating Activities 0.00355
Capital Expenditures -0.10646
Jan 2023 Oct 2022 Jul 2022 Apr 2022 Jan 2022
Net income/Starting Line -11.5726 -6.14707 -3.03707 -12.3621 -8.49266
Cash From Operating Activities -6.68797 -4.881 -2.53669 -6.61399 -5.05164
Non-Cash Items 3.0913 1.58298 0.86734 4.41734 3.16357
Changes in Working Capital 1.77563 -0.32933 -0.37405 1.32718 0.27745
Cash From Investing Activities -0.10646 0
Other Investing Cash Flow Items, Total 0 0
Cash From Financing Activities 0 0 0 18.855 14.9127
Financing Cash Flow Items -0.05867 0
Issuance (Retirement) of Stock, Net 0 0 0 18.9137 14.9127
Issuance (Retirement) of Debt, Net 0 0
Net Change in Cash -6.68797 -4.881 -2.53669 12.1345 9.86102
Cash From Operating Activities 0.01774 0.01242 0.0071 0.00355
Capital Expenditures -0.10646

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Alzamend Neuro, Inc. Company profile

About Alzamend Neuro Inc

Alzamend Neuro, Inc. is a preclinical stage biopharmaceutical company focused on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The Company's pipeline consists of two therapeutic drug candidates: AL001 and AL002. The AL001 is a cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001 or LiProSal, through two royalty-bearing worldwide licenses from the University of South Florida Research Foundation, Inc. (licensor). AL002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s, known as AL002 or CA022W, through a royalty-bearing worldwide license from the licensor.

Financial summary

BRIEF: For the nine months ended 31 January 2022, Alzamend Neuro Inc revenues was not reported. Net loss increased from $3.8M to $8.5M. Higher net loss reflects Research and development - Bal increase from $953K to $3.2M (expense), Stock-based Compensation in SGA increase of 67% to $2.8M (expense), General and administrative - Bal increase from $547K to $1.1M (expense).

Industry: Biotechnology & Medical Research (NEC)

3480 Peachtree Road NE,
Second Floor, Suite 103
ATLANTA
GEORGIA 30326
US

Income Statement

  • Annual
  • Quarterly

News

December RBA preview: no move expected at the final meeting of 2023

The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

14:47, 4 December 2023

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023

People also watch

XRP/USD

0.62 Price
-6.740% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

BTC/USD

41,887.25 Price
-4.330% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Gold

1,987.09 Price
-0.880% 1D Chg, %
Long position overnight fee -0.0199%
Short position overnight fee 0.0117%
Overnight fee time 22:00 (UTC)
Spread 0.50

US100

16,149.90 Price
+0.400% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading